Endo International (NASDAQ:ENDP) (TSE:ENL) had its target price hoisted by equities researchers at Cantor Fitzgerald from $12.00 to $18.00 in a research note issued on Friday, October 19th, The Fly reports. The brokerage presently has a “neutral” rating on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 33.43% from the company’s current price.
Other equities research analysts also recently issued research reports about the stock. Royal Bank of Canada upgraded shares of Endo International from a “sector perform” rating to an “outperform” rating and set a $26.00 target price for the company in a research report on Monday, August 13th. Zacks Investment Research upgraded shares of Endo International from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research report on Monday, September 24th. Goldman Sachs Group upgraded shares of Endo International from a “sell” rating to a “neutral” rating and increased their target price for the stock from $14.00 to $15.00 in a research report on Tuesday, September 11th. TheStreet upgraded shares of Endo International from a “d” rating to a “c-” rating in a research report on Monday, August 20th. Finally, BidaskClub downgraded shares of Endo International from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 8th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $14.97.
Shares of NASDAQ:ENDP traded up $0.30 during mid-day trading on Friday, hitting $13.49. The stock had a trading volume of 6,440,068 shares, compared to its average volume of 4,723,015. The company has a market cap of $3.59 billion, a PE ratio of 3.51, a price-to-earnings-growth ratio of 1.54 and a beta of 0.65. Endo International has a 12-month low of $5.27 and a 12-month high of $18.50.
In other Endo International news, Director Roger H. Kimmel sold 26,074 shares of the firm’s stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $15.90, for a total value of $414,576.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 0.80% of the company’s stock.
Several institutional investors have recently modified their holdings of ENDP. Xact Kapitalforvaltning AB boosted its position in shares of Endo International by 44.5% during the 1st quarter. Xact Kapitalforvaltning AB now owns 29,215 shares of the company’s stock valued at $174,000 after acquiring an additional 9,000 shares in the last quarter. James Investment Research Inc. boosted its position in shares of Endo International by 594.9% during the 3rd quarter. James Investment Research Inc. now owns 10,945 shares of the company’s stock valued at $184,000 after acquiring an additional 9,370 shares in the last quarter. Harvest Fund Management Co. Ltd acquired a new stake in shares of Endo International during the 3rd quarter valued at about $223,000. Cim Investment Mangement Inc. acquired a new stake in shares of Endo International during the 3rd quarter valued at about $262,000. Finally, First Hawaiian Bank acquired a new stake in shares of Endo International during the 3rd quarter valued at about $358,000. Institutional investors and hedge funds own 98.43% of the company’s stock.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Featured Story: What is the 52-week high/low?
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.